An interventional study of Dexamethasone in Acute Respiratory Distress Syndrome and Respiratory Distress Syndrome, Acute, sponsored by The Second Affiliated Hospital of Chongqing Medical University. Recruiting at 1 site in China. Open to female participants. Per ClinicalTrials.gov, last updated 2025-06-04.
Sponsored by The Second Affiliated Hospital of Chongqing Medical University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing dexamethasone in Respiratory Distress Syndrome — 4 open to participants now, 5 under way, 2 of them phase 3. Dexamethasone · Respiratory Distress Syndrome.
Among the 14 studies testing dexamethasone in Respiratory Distress Syndrome, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2024, is one of 2 with no phase, and was the 10th registered.
1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 282 are open to participants now.
Browse Respiratory Distress Syndrome studies →4 of the 14 studies testing dexamethasone in Respiratory Distress Syndrome are open now, in 2 countries. Recruiting first, the newest first:
Southeast University, China · Sites in China
Peking Union Medical College Hospital · Sites in China
Ages 18+
Centre Hospitalier Régional Metz-Thionville · Sites in France
Ages 18+
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 193 Respiratory Distress Syndrome studies recruiting now, 117 (61%) set no upper age limit and 48 (25%) stop at 75 or younger; 50 take children under 18; 9 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 9 · Phase 4 2
First in 1976; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 60 across 822 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 299 across the 13 interventional studies. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
The Second Affiliated Hospital of Chongqing Medical University is the lead sponsor of 103 studies on the registry; 33 are open to participants now.
The Second Affiliated Hospital of Chongqing Medical University has 1 study filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing dexamethasone in Respiratory Distress Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
For neonates with a probability greater than 80% in the prediction model of ARDS, at least one ACS was given before the termination of pregnancy. The GC level of cord blood (taken at birth) and the mRNA levels of α-ENaC, Na-K-atpase and SGK1 in nasal epithelium were measured within 2 hours and 1 day after birth in the ACS intervention group and the control group. The occurrence and severity of pulmonary edema, the occurrence and severity of ARDS, and the mortality rate of NARDS were evaluated by lung ultrasound. The indexes of the two groups were compared horizontally and longitudinally.
Based on the proposed scientific hypothesis, the project team intends to achieve the following research objectives through scientific experiments:
To explore the role of ACS in promoting fetal lung maturation from the perspective of lung fluid clearance through the traditional concept that ACS promotes fetal lung maturation mainly by inducing PS, so as to further expand the object and scope of ACS application.
The prenatal prediction model of ARDS was established by using perinatal risk factors, and the predictive value was visualized.
To explore the clinical value and mechanism of ACS in pregnant women at high risk of NARDS, and to open up new ideas for the prevention and treatment of NARDS from the perspective of promoting lung fluid clearance; The early prevention and treatment strategy of NARDS was established by combining the "prenatal prediction model +ACS", and its effect was evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A predictive model for neonatal acute respiratory distress syndrome was established based on perinatal risk factors.
Inclusion Criteria:
Exclusion Criteria:
For pregnant women with a probability greater than 80% in the prediction model of NARDS, those who agreed to ACS intervention were included in the experimental group
Drug: Dexamethasone
For pregnant women with a probability greater than 80% in the prediction model of NARDS, those who did not agree with ACS intervention were included in the control group
ACS intervention were used in the experimental group
Also known as: antenatal corticosteroids
The incidence and severity of neonatal acute respiratory distress syndrome
The incidence and severity of neonatal acute respiratory distress syndrome will be compared between the two groups
Time frame: 1 year
The incidence and severity of pulmonary edema
The incidence and severity of pulmonary edema will be compared between the two groups
Time frame: 1 year
The mortality of NARDS
The mortality rate of NARDS will be compared between the two groups
Time frame: 1 year
The mRNA levels of α-ENaC, Na-K-atpase, and SGK1 in nasal epithelium
The mRNA levels of α-ENaC, Na-K-atpase, and SGK1 in nasal epithelium will be compared between the two groups
Time frame: Day 0 after birth
The glucocorticoid level in cord blood
The glucocorticoid levels of cord blood will be compared between the two groups
Time frame: Day 0 after birth
Plan to share: No
Started Feb 2024 (actual). Primary completion is estimated for Dec 2025, 22 months after the start.
Of 264 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 22 months is close to that.
Counting every sponsor, half of 271 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
Respiratory Distress Syndrome →
The Second Affiliated Hospital of Chongqing Medical University →